stocks logo

TERN Valuation

Terns Pharmaceuticals Inc
$
3.010
-0.290(-8.790%)
  • Overview
  • Forecast
  • Valuation

TERN Relative Valuation

TERN's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, TERN is overvalued; if below, it's undervalued.

Historical Valuation

P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
0.83
P/B
Median3y
1.51
Median5y
1.40
-22.93
FCF Yield
Median3y
-22.68
Median5y
-22.98

Competitors Valuation Multiple

The average P/S ratio for TERN's competitors is 7.49, providing a benchmark for relative valuation. Terns Pharmaceuticals Inc Corp (TERN) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

FAQ

arrow icon

Is Terns Pharmaceuticals Inc (TERN) currently overvalued or undervalued?

Terns Pharmaceuticals Inc (TERN) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of 11.88. The fair price of Terns Pharmaceuticals Inc (TERN) is between to according to relative valuation methord.
arrow icon

What is Terns Pharmaceuticals Inc (TERN) fair value?

arrow icon

How does TERN's valuation metrics compare to the industry average?

arrow icon

What is the current P/B ratio for Terns Pharmaceuticals Inc (TERN) as of May 07 2025?

arrow icon

What is the current FCF Yield for Terns Pharmaceuticals Inc (TERN) as of May 07 2025?

arrow icon

What is the current Forward P/E ratio for Terns Pharmaceuticals Inc (TERN) as of May 07 2025?

arrow icon

What is the current Forward P/S ratio for Terns Pharmaceuticals Inc (TERN) as of May 07 2025?